Baslund Bo
Rigshospitalet, Reumatologisk Klinik TA, København Ø.
Ugeskr Laeger. 2008 Jun 9;170(24):2150-2.
The current status of the use of biological medicine in the treatment of adult onset morbus still, Wegeners granulomatosis and systemic lupus erythematosus (SLE) is reviewed. The need for controlled trials is emphasized. Anti-CD20 treatment for SLE patients with kidney involvement and patients with Wegeners granulomatosis seems promising. Anti-TNF and IL1 receptor antagonist can control disease activity in most patients with adult morbus still.
本文综述了生物药物在治疗成人斯蒂尔病、韦格纳肉芽肿病和系统性红斑狼疮（SLE）方面的应用现状。强调了进行对照试验的必要性。抗CD20治疗对于有肾脏受累的SLE患者和韦格纳肉芽肿病患者似乎很有前景。抗TNF和IL1受体拮抗剂可控制大多数成人斯蒂尔病患者的疾病活动。
